Genmab A/S (GMAB) Announces FDA Extension of sBLA Review, Submitted by Novartis (NVS), for Ofatumumab in Relapsing Multiple Sclerosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Genmab A/S (GMAB) PT Raised to $36 at SunTrust
June 2, 2020 6:58 AM EDTSunTrust analyst Asthika Goonewardene raised the price target on Genmab A/S (NASDAQ: GMAB) to $36.00 (from $30.00) while maintaining a Buy rating.... More
Genmab A/S (GMAB) PT Raised to $36 at SunTrust; 'Product Potential, Pipeline and Platform'
June 1, 2020 11:00 AM EDTSunTrust analyst Asthika Goonewardene raised the price target on Genmab A/S (NASDAQ: GMAB) to $36.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "We are raising our PT as recent developments make us better appreciate GMAB's pipeline & platform. We're more favorable on... More
Genmab A/S (GMAB) PT Raised to $34 at H.C. Wainwright After DARZALEX Combo Results
June 1, 2020 6:59 AM EDTH.C. Wainwright analyst Raghuram Selvaraju raised the price target on Genmab A/S (NASDAQ: GMAB) to $34.00 (from $29.00) while maintaining a Buy rating after the company announced positive top-line results for the combination of subcutaneous DARZALEX + cyclophosphamide, bortezomib and dexamethasone (CyBorD) vs CyBorD alone from... More
UBS Reiterates Buy Rating on Genmab A/S (GEN:DC) (GMAB)
June 1, 2020 5:38 AM EDTUBS analyst Laura Sutcliffe reiterated a Buy rating and DKK2,500.00 price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB).
... MoreGenmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Citi
June 1, 2020 5:13 AM EDTCiti raised its price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,500.00 (from DKK1,600.00) while maintaining a Buy rating.... More
